Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Age matters: study measures exact ciprofol dose for loss of consciousness

NCT ID NCT07148596

Knowledge-focused Sponsor: General Hospital of Ningxia Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 125 patients of different ages to find out how much ciprofol (an anesthetic drug) they needed to lose consciousness. Researchers measured the dose and brain activity (bispectral index) during anesthesia induction. The goal is to help doctors tailor ciprofol doses more precisely for safer anesthesia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ciprofol
What this could lead to
If successful, this could help anesthesiologists give safer, more personalized doses of ciprofol based on a patient's age.
What could go wrong
This is a small, single-center observational study, not a large trial. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

125 people

The number who actually took part.

Started

Sep 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A total of 120 patients scheduled for general anesthesia were selected according to inclusion/exclusion criteria, with balanced age distribution and equal gender allocation (60 males and 60 females).

Ages

3 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\) The ASA classification I-II 2) BMI range: 18.5 \< BMI ≤ 24.9 kg/m² 3) Scheduled for elective general anesthesia surgery 4) Signed informed consent by the patient or legal guardian Exclusion Criteria: * 1\) Patients with central nervous system disorders or using medications affecting the central nervous system 2) Patients with cardiac, hepatic, pulmonary, or renal dysfunction 3) History of alcohol or drug abuse 4) Allergy to the study drug 5) Patients with hematologic or metabolic diseases 6) Participation in other drug clinical trials within the past 4 weeks 7) Refusal to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ciprofol are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

channelopathy-associated congenital insensitivity to pain, autosomal recessive hereditary sensory and autonomic neuropathy Unconsciousness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ciprofol

Contacts and locations

Locations

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.